Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 71Prostatic Neoplasms 22Kidney Neoplasms 14Carcinoma, Transitional Cell 9Urinary Bladder Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Hepatocellular 6Urethral Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Wilms Tumor 2Urologic Neoplasms 2Urogenital Neoplasms 2Ureteral Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Recurrence 2Penile Neoplasms 2Pancreatic Neoplasms 2Pain 2Osteosarcoma 2Melanoma 2

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2pembrolizumab 1enfortumab vedotin 1cabozantinib 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × cabozantinib × Genitourinary × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡